S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Rosemont Agrees to Buy Aytu BioPharma for $29.3 Million

Rosemont Pharmaceuticals has agreed to acquire Aytu BioPharma for $2.70 per share in an all-cash deal valued at about $29.3 million, based on Aytu’s 10.87 million outstanding shares. The transaction is expected to close in late December.

Rosemont Agrees to Buy Aytu BioPharma for $29.3 Million

The deal will begin with a tender offer. Aytu will tender shares representing at least a majority of its outstanding stock, after which Rosemont would acquire any remaining shares through a merger. Aytu’s board has approved the transaction.

Aytu develops medicines for complex central nervous system diseases. The acquisition is intended to strengthen Rosemont’s position in the specialty pharmaceutical market. Rosemont is backed by private-equity firm Inflexion.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!